Colgate-Palmolive Files Definitive Proxy Statement

Ticker: CL · Form: DEF 14A · Filed: 2024-03-27T00:00:00.000Z

Sentiment: neutral

Topics: Colgate-Palmolive, DEF 14A, Proxy Statement, Executive Compensation, Shareholder Voting

TL;DR

<b>Colgate-Palmolive Co. has filed its Definitive Proxy Statement for the period ending May 10, 2024.</b>

AI Summary

COLGATE PALMOLIVE CO (CL) filed a Proxy Statement (DEF 14A) with the SEC on March 27, 2024. Colgate-Palmolive Co. filed a Definitive Proxy Statement (DEF 14A) on March 27, 2024. The filing covers the period ending May 10, 2024. The company's Central Index Key is 0000021665. Colgate-Palmolive's fiscal year ends on December 31. The filing includes data related to PEO (Performance Equity Option) awards for the years 2020-2023.

Why It Matters

For investors and stakeholders tracking COLGATE PALMOLIVE CO, this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation, voting matters, and corporate governance before the annual meeting. It provides detailed financial and operational information relevant to investment decisions and proxy voting.

Risk Assessment

Risk Level: low — COLGATE PALMOLIVE CO shows low risk based on this filing. The filing is a routine proxy statement and does not contain new material financial information or significant strategic shifts that would inherently increase risk.

Analyst Insight

Shareholders should review the proxy statement to understand executive compensation packages and vote on proposals at the upcoming annual meeting.

Key Numbers

Key Players & Entities

FAQ

When did COLGATE PALMOLIVE CO file this DEF 14A?

COLGATE PALMOLIVE CO filed this Proxy Statement (DEF 14A) with the SEC on March 27, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by COLGATE PALMOLIVE CO (CL).

Where can I read the original DEF 14A filing from COLGATE PALMOLIVE CO?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by COLGATE PALMOLIVE CO.

What are the key takeaways from COLGATE PALMOLIVE CO's DEF 14A?

COLGATE PALMOLIVE CO filed this DEF 14A on March 27, 2024. Key takeaways: Colgate-Palmolive Co. filed a Definitive Proxy Statement (DEF 14A) on March 27, 2024.. The filing covers the period ending May 10, 2024.. The company's Central Index Key is 0000021665..

Is COLGATE PALMOLIVE CO a risky investment based on this filing?

Based on this DEF 14A, COLGATE PALMOLIVE CO presents a relatively low-risk profile. The filing is a routine proxy statement and does not contain new material financial information or significant strategic shifts that would inherently increase risk.

What should investors do after reading COLGATE PALMOLIVE CO's DEF 14A?

Shareholders should review the proxy statement to understand executive compensation packages and vote on proposals at the upcoming annual meeting. The overall sentiment from this filing is neutral.

Key Dates

Glossary

DEF 14A
Definitive Proxy Statement (This is the primary filing type for this document, indicating it's a formal statement for shareholders regarding company matters.)
PEO
Performance Equity Option (Refers to a type of executive compensation award, data for which is included in the filing.)

Filing Stats: 4,304 words · 17 min read · ~14 pages · Grade level 16.5 · Accepted 2024-03-27 08:29:47

Key Financial Figures

Filing Documents

Executive Compensation

Executive Compensation 28 Compensation Discussion and Analysis 28 P&O Committee Report 43 Summary Compensation Table 44 Grants of Plan-Based Awards 46 Outstanding Equity Awards at Fiscal Year-End 47 Option Exercises and Stock Vested 48 Retirement Plans 48 Deferred Compensation Plan 50 Supplemental Savings & Investment Plan 51 Executive Severance and Other Termination Benefits 52 CEO Pay Ratio 55 Pay Versus Performance 56 Stock Ownership 59 Stock Ownership of Directors and Executive Officers 59 Stock Ownership of Certain Beneficial Owners 60 Proposals Requiring Your Vote 61 Proposal 1: Election of Directors 61 Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm (includes Audit Committee Report) 61 Proposal 3: Advisory Vote on Executive Compensation 64 Proposal 4: Stockholder Proposal 64 Other Matters 66 Questions and Answers About Our Annual Meeting 67 Annex A—Reconciliation of Non-GAAP Financial Measures A-1 Table of Contents Proxy Statement Summary This summary highlights information about Colgate-Palmolive Company (referred to in this Proxy Statement as "we," "us," "our," "Colgate" or the "Company") and our upcoming 2024 Annual Meeting of Stockholders (the "Annual Meeting") contained elsewhere in this Proxy Statement. This summary does not contain all of the information you should consider, and you should read the entire Proxy Statement carefully before voting. About Colgate Our Purpose: We are a caring, innovative growth company reimagining a healthier future for all people, their pets and our planet. We seek to deliver sustainable, profitable growth and superior shareholder returns, as well as to provide Colgate people with an innovative and inclusive work environment. We do this by developing and selling science-led products globally that make people's and their pets' lives healthier and more enjoyable and by embracing our s

Executive Compensation Program Highlights

Executive Compensation Program Highlights The key principles underlying our compensation philosophy are aligning pay and performance, driving strong business results and our strategic plan, focusing on long-term shareholder return, motivating and retaining critical talent and reflecting external market and competitive practices. In 2023, the compensation of the Named Officers (as defined in the Compensation Discussion and Analysis, or "CD&A") was designed so that approximately 75% to 90% of their target direct compensation (salary and target annual and long-term incentives) would be incentive compensation. Annual and long-term incentive award payments vary from target levels based on our business performance, and long-term incentive award payments and the value of equity awards also vary based on the performance of our common stock ("Common Stock"). Our executive compensation program for 2022 received substantial stockholder support and was approved, on an advisory basis, by 89.3% of stockholders voting on the proposal at the 2023 Annual Meeting of Stockholders. Evolution of Long-Term Incentive Compensation Structure In 2023, the Board's compensation committee, known as the Personnel and Organization Committee (the "P&O Committee"), oversaw a review of our long-term incentive compensation structure and, with support from the other independent directors, determined to add an additional type of equity to our long-term incentive program. Through 2022, we used two types of long-term incentives for officers, each weighted 50%: performance-based restricted stock units ("PBRSUs") and stock options. Starting in 2023, PBRSUs continued to comprise 50% of the long-term incentive program for officers, while stock options comprised 30% and time-based restricted stock units ("RSUs") comprised 20%. The P&O Committee believes the new structure better aligns with market standards and practice, while still focusing on growth and driving long-term performance and retention

View on Read The Filing